research use only
Cat.No.S1490
| Related Targets | EGFR VEGFR JAK FGFR PDGFR Src HIF FLT3 HER2 FLT |
|---|---|
| Other Bcr-Abl Inhibitors | Degrasyn (WP1130) Bafetinib (INNO-406) Rebastinib (DCC-2036) GNF-5 Berbamine GNF-2 Olverembatinib dimesylate (GZD824) PD173955 GNF-7 Berbamine dihydrochloride |
|
In vitro |
DMSO
: 73 mg/mL
(137.07 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about Ponatinib (AP24534) solubility in DMSO or water
Read more about Ponatinib (AP24534) working concentrations for cell culture treatment
| Information | Ponatinib (AP24534) is a potent, ATP-competitive multi-kinase (BCR-ABL, FGFR, PDGFR) inhibitor. It affects PI3K/AKT, MAPK/ERK, and STAT signaling pathways by binding to the kinase ATP-binding site, effectively inhibiting tumor cell proliferation and inducing apoptosis. |
|---|---|
|
Read more about Ponatinib (AP24534) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
Read more about Ponatinib (AP24534) Mechanism of Action Clinical Trials
| Molecular Weight | 532.56 | Formula | C29H27F3N6O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 943319-70-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | AP24534 | SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 | ||
Read more about storage stability stock solution CAS number SMILES
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM solution in DMSO is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for this compound is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.